estimated annual operating cost disclosures must be based on the 1995 DOE cost figures published in this notice. The labels must also disclose, under the secondary estimated annual operating cost disclosure, the fact that the estimated annual operating cost is based on the appropriate 1995 DOE energy cost figure. Manufacturers of the above-mentioned products must make these disclosures on the labels required by the amendments and in catalogs beginning ninety days after the Commission publishes new energy consumption ranges of comparability based on the 1995 submissions required by § 305.8. They must continue to use the 1995 DOE cost figures in the manner just described until the Commission publishes new ranges of comparability based on future annual submissions of estimated annual energy consumption data. At that time, these manufacturers must use the then-current DOE energy cost figures when they prepare new labels in response to the new energy consumption ranges of comparability. When such new ranges are published, the effective date for labeling new products will be ninety days after publication of the ranges in the **Federal Register**. As in the past, products that have been properly labeled prior to the effective date of any range modification need not be relabeled.

For Energy Cost Representations Respecting Products Covered by EPCA but Not by the Commission's Rule

Manufacturers of products covered by section 323(c) of EPCA, but not by the Appliance Labeling Rule (clothes dryers, television sets, kitchen ranges and ovens, and space heaters) must use the 1995 representative average unit costs for energy in all operating cost representations beginning May 18, 1995.

List of Subjects in 16 CFR Part 305

Advertising, Energy conservation, Household appliances, Labeling, Reporting and recordkeeping requirements.

PART 305—[AMENDED]

Accordingly, 16 CFR Part 305 is amended as follows:

1. The authority citation for part 305 continues to read as follows:

Authority: 42 U.S.C. 6294.

2. Section 305.9(a) is revised to read as follows:

§ 305.9 Representative average unit energy costs.

(a) Table 1, below, contains the representative unit energy costs to be utilized for all requirements of this part.

TABLE 1.—REPRESENTATIVE AVERAGE UNIT COSTS OF ENERGY FOR FIVE RESIDENTIAL ENERGY SOURCES (1995)

Type of energy	In common terms	As required by DOE test procedure	Dollars per million Btu [1]
Electricity	8.67¢/kWh [2 3]	$0.0867/kWh	$25.41
Natural Gas	63.0¢/therm [4] or $6.49/MCF [5 6].	0.00000630/Btu	6.30
No. 2 heating oil	1.008/gallon [7]	0.00000727/Btu	7.27
Propane	0.985/gallon [8]	0.00001079/Btu	10.79
Kerosene	1.094/gallon [9]	0.00000810/Btu	8.10

[1] Btu stands for British thermal unit.
[2] kWh stands for kilowatt hour.
[3] 1 kWh=3,412 Btu.
[4] 1 therm=100,000 Btu. Natural gas prices include taxes.
[5] MCF stands for 1,000 cubic feet.
[6] For the purposes of this table, 1 cubic foot of natural gas has an energy equivalence of 1,030 Btu.
[7] For the purposes of this table, 1 gallon of No. 2 heating oil has an energy equivalence of 138,690 Btu.
[8] For the purposes of this table, 1 gallon of liquid propane has an energy equivalance of 91,333 Btu.
[9] For the purposes of this table, 1 gallon of kerosene has an energy equivalence of 135,000 Btu.

* * * * *

Donald S. Clark,

Secretary.

[FR Doc. 95–4010 Filed 2–16–95; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 14

Advisory Committees; Amendments

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the standing advisory committees' regulations to change the function of the Anti-Infective Drugs Advisory Committee and to change the name and the function of the Dermatologic Drugs Advisory Committee. This action is being taken due to an administrative transfer of functions for the committees in the review of human drug products for use in the treatment of ophthalmic disorders.

EFFECTIVE DATE: February 17, 1995.

FOR FURTHER INFORMATION CONTACT: Donna M. Combs, Committee Management Office (HFA–306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–2765.

SUPPLEMENTARY INFORMATION:

FDA is revising § 14.100(c)(2) (21 CFR 14.100(c)(2)) to remove the review of human drug products for use in the treatment of ophthalmic disorders from the function of the Anti-Infective Drugs Advisory Committee. The review of human drug products for use in the treatment of ophthalmic disorders has been transferred to the Dermatologic and Ophthalmic Drugs Advisory Committee (formerly the Dermatologic Drugs Advisory Committee). The function of the Anti-Infective Drugs Advisory Committee was revised in the charter renewal dated October 3, 1994. In this document, FDA is formally changing the function of the committee.

FDA is also revising § 14.100(c)(6) to change the name and the function of the Dermatologic Drugs Advisory Committee. The function of the committee has been amended to include the review of human drug products for use in the treatment of ophthalmic disorders. The name was changed to reflect the committee's revised function. In the **Federal Register** of December 6, 1994 (59 FR 62734), FDA published a notice of charter renewals dated October 3, 1994, for the Anti-Infective Drugs Advisory Committee and the Dermatologic and Ophthalmic Drugs Advisory Committee. In that notice, the